Advertisement
The new divisions include an In Vitro Diagnostics (IVD) divisionspecifically focused on accelerating AMDL's market launch for the AMDL-ELISADR-70(R) (FDP) cancer test; a Cancer Therapeutics division specificallyfocused on accelerating research for its Combination Immunogene Therapy (CIT)technology; and a China-based Integrated Pharmaceuticals division focused onthe continued manufacturing, sales and distribution of AMDL's broad range ofgeneric, specialty and branded pharmaceutical products.
Advertisement
AMDL will continue to execute its 2008 business plan with a focus onachieving its stated financial target of a 100% increase in sales over 2007.Additionally, under this new operational structure, AMDL will aggressivelywork to:
"Segmenting AMDL's operations into these three distinct divisions providesus with greater market focus, increased flexibility across our diverse productportfolio, and a solid platform to successfully execute AMDL's key businessgoals," commented Mr. Gary Dreher, President and CEO of AMDL. "We've achievedsignificant growth in sales and gross profits over the past 18 months andbelieve this refinement will strengthen AMDL's long-term growth position as aleading developer, manufacturer and supplier of high-quality diagnostic andpharmaceutical products."
For additional information on AMDL and its diversified product portfoliovisit the Company's website at http://www.amdl.com or contact AMDL InvestorRelations at 206.310.5323.
About AMDL:
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, andJilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc.(JPI), is a vertically integrated bio-pharmaceutical company devoted to theresearch, development, manufacturing, and marketing of diagnostic,pharmaceutical, nutritional supplement, and cosmetic products. The companyemploys approximately 320 people in the U.S. and China. The Company has anadditional 4 pharmaceutical and diagnostic products under review by variousregulatory authorities.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Actof 1995: The statements contained in this document include certain predictionsand projections that may be considered forward-looking statements undersecurities law. These statements involve a number of important risks anduncertainties that could cause actual results to differ materially including,but not limited to, the performance of joint venture partners, as well asother economic, competitive and technological factors involving the Company'soperations, markets, services, products, and prices. With respect to AMDLInc., except for the historical information contained herein, the mattersdiscussed in this document are forward-looking statements involving risks anduncertainties that could cause actual results to differ materially from thosein such forward-looking statements. Potential risks and uncertainties relatedto the Company's access to additional capital, competition and dependence onkey management.-- Establish the IVD division for DR-70 with a structural platform for funding the division through a potential joint-venture partnership(s) or selling the division as a stand-alone business; -- Establish the Cancer Therapeutics division with a structural platform for funding the division through a potential joint-venture partnership(s) or selling the division as a stand-alone business; -- Continue accelerating the manufacturing, sales & marketing of AMDL's diverse China-based pharmaceutical product portfolio through the Integrated Pharmaceuticals division; and, -- Leverage AMDL's current assets and resources to drive future growth.
SOURCE AMDL, Inc.
